The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.
Empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT2) inhibitor is being studied for treatment of patients with Type 2 Diabetes (T2D) by Boehringer Ingelheim and Eli Lilly and Company.
In four clinical trials to date, SGLT2 inhibitors have been shown to reduce blood glucose by inhibiting glucose reabsorption in the kidney, resulting in significant change in HbA1c independently of beta cell function and insulin resistance.
Empagliflozin (10 and 25 mg) taken once daily showed incidence of adverse events was similar for placebo. Compared with placebo, genital infections occurred more frequently with empagliflozin at both the 10 mg and the 25 mg dosages.
Boehringer Ingelheim and Lilly anticipate filing for regulatory review in the U.S., Europe and Japan in 2013. Boehringer Ingelheim and Lilly plan to present detailed data disclosures for many of these studies at scientific medical meetings and publications in 2013 and 2014.
Sign up for
Follow the medications that matter most to
you and Ask related questions.
Receive email notifications as soon as your
medication pages are updated.